AQST
NASDAQ · Pharmaceuticals
Aquestive Therapeutics Inc
$3.61
-0.05 (-1.37%)
Financial Highlights (FY 2026)
Revenue
49.93M
Net Income
-93,917,120
Gross Margin
58.3%
Profit Margin
-188.1%
Rev Growth
-2.2%
D/E Ratio
4.68
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 58.3% | 58.3% | 55.1% | 55.1% |
| Operating Margin | -159.5% | -143.5% | 28.0% | 27.5% |
| Profit Margin | -188.1% | -178.7% | 25.7% | 25.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 49.93M | 51.08M | 128.94M | 106.66M |
| Gross Profit | 29.13M | 29.80M | 71.02M | 58.74M |
| Operating Income | -79,639,823 | -73,318,167 | 36.05M | 29.37M |
| Net Income | -93,917,120 | -86,462,160 | 33.13M | 27.21M |
| Gross Margin | 58.3% | 58.3% | 55.1% | 55.1% |
| Operating Margin | -159.5% | -143.5% | 28.0% | 27.5% |
| Profit Margin | -188.1% | -178.7% | 25.7% | 25.5% |
| Rev Growth | -2.2% | -2.2% | +19.1% | -7.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 186.17M | 186.17M | 204.59M | 185.15M |
| Total Equity | 39.76M | 39.76M | 356.51M | 373.84M |
| D/E Ratio | 4.68 | 4.68 | 0.57 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -79,031,328 | -76,800,083 | 53.66M | 42.58M |
| Free Cash Flow | — | — | 23.71M | 15.65M |